Assessment of Communication Strategies for Mitigating COVID-19 Vaccine-Specific Hesitancy in Canada [open pdf - 812KB]
From the Introduction: "Mass vaccination campaigns are rapidly proceeding globally. These campaigns make use of vaccines with different characteristics, such as their country of origin, number of required doses, underlying technology (eg, mRNA [Messenger ribonucleic acid]), and their levels of efficacy and safety. Containing the COVID-19 [coronavirus disease 2019] pandemic will require vaccinating at least 70% of US individuals and billions more globally. It will also likely require follow-up or booster vaccinations. Understanding the sources of hesitancy and identifying correctives is, thus, vitally important for global public health. Important research identifies sources of COVID-19 vaccine hesitancy. Resistance appears to be higher among people with low trust in expertise and, in the US, among Republican party identifiers. Vaccine hesitancy is also higher among racial and ethnic minority groups, women, those with more skepticism about childhood vaccines, and those skeptical of the severity of the COVID-19 pandemic. This work aligns with findings on which groups of citizens are more likely to comply with public health directives on mask usage and social distancing and broader findings on vaccine hesitancy outside of the COVID-19 context. [...] . In this study, we examine whether providing information on the effectiveness of the AstraZeneca and Johnson & Johnson vaccines at preventing death from COVID-19 increases people's confidence in their effectiveness and reduces their hesitancy toward these vaccines. We also explore whether this information can mitigate possible negative consequences that arise from providing information on the comparatively less-impressive record of these vaccines at preventing symptomatic COVID-19 infection."
2021 Merkley E et al. Posted here with permission. Document is under a Creative Commons license and requires proper attribution and noncommercial use to be shared: [https://creativecommons.org/licenses/by/4.0/].
JAMA Network: https://jamanetwork.com/
JAMA Network Open (September 30, 2021), v.4 no.9